The UCI has sent out a press release advising that Australian rider Michael Rogers has been provisionally suspended in response to a report from the WADA-accredited laboratory in Tokyo indicating an adverse analytical finding of clenbuterol in a urine sample collected from him in a test during the Japan Cup Cycle Road Race on 20 October 2013.
The provisional suspension of Mr. Michael Rogers remains in force until a hearing panel convened by his national federation determines whether he has committed an anti-doping rule violation under Article 21 of the UCI Anti-Doping Rules.
Mr. Rogers has the right to request and attend the analysis of his B sample.
Under the World Anti-Doping Code and the UCI Anti-Doping Rules, the UCI is unable to provide any additional information at this time.
Rogers’ victory at the Japan Cup was his only win of the 2013 season which and came after he attacked alone at the end of a rain-soaked day in Utsunomiya.
In a Saxo-Tinkoff team statement, Mick Rogers explained to the team management that he never ingested the substance knowingly nor deliberately and fears that the adverse analytical finding origins from a contaminated food source. Rogers participated in Tour of Beijing the week before the Japan Cup and travelled directly from China to Japan.
Jonathan Breyne, who rides with the To Win-Josan team, also returned an A sample for clenbuterol — a drug used to treat conditions such as asthma, and therefore with the potential to make improve athletes’ breathing. However, stripping off fat and adding lean mass is why athletes abuse the substance. Clenbuterol is also still used in the cattle industry in some countries for the same purposes.
The substance was found in a urine sample provided by the 22-year-old during the Tour of Taihu Lake in China on November 5, the UCI said.
The provisional suspension will likewise remain in force until the Belgian cycling federation determines whether Breyne committed a doping violation, and he likewise has the right to seek and attend the analysis of a B sample.